<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Genet</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-8021</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7046682</article-id>
    <article-id pub-id-type="doi">10.3389/fgene.2019.01378</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Genetics</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OSgbm: An Online Consensus Survival Analysis Web Server for Glioblastoma</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Dong</surname>
          <given-names>Huan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/734374"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Ning</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/885245/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lv</surname>
          <given-names>Jiajia</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/629942"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ge</surname>
          <given-names>Linna</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Mengsi</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Guosen</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/695335"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>An</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/743108"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Fengling</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xie</surname>
          <given-names>Longxiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/685683"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yongqiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/584021"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Wan</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/677026"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Haiyu</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Minghang</given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/605469"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Software, School of Basic Medical Sciences, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Anesthesia, Stanford University School of Medicine</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Department of Pathology, Stanford University School of Medicine</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country></aff>
    <aff id="aff4"><sup>4</sup><institution>Nanjing Jiliang Biotechnology Co., Ltd.</institution>, <addr-line>Nanjing</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Meng Zhou, Wenzhou Medical University, China</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Zhixiang Zuo, Sun Yat-sen University, China; Xuexin Yu, UT Southwestern Medical Center, United States</p>
      </fn>
      <corresp id="fn001">*Correspondence: Xiangqian Guo, <email xlink:href="mailto:xqguo@henu.edu.cn" xlink:type="simple">xqguo@henu.edu.cn</email>
</corresp>
      <fn fn-type="equal" id="fn002">
        <p>†These authors have contributed equally to this work</p>
      </fn>
      <fn fn-type="other" id="fn003">
        <p>This article was submitted to Cancer Genetics, a section of the journal Frontiers in Genetics</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>21</day>
      <month>2</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2019</year>
    </pub-date>
    <volume>10</volume>
    <elocation-id>1378</elocation-id>
    <history>
      <date date-type="received">
        <day>08</day>
        <month>5</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>17</day>
        <month>12</month>
        <year>2019</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 Dong, Wang, Li, Lv, Ge, Yang, Zhang, An, Wang, Xie, Li, Zhu, Zhang, Zhang and Guo</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>Dong, Wang, Li, Lv, Ge, Yang, Zhang, An, Wang, Xie, Li, Zhu, Zhang, Zhang and Guo</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Glioblastoma (GBM) is the most common malignant tumor of the central nervous system. GBM causes poor clinical outcome and high mortality rate, mainly due to the lack of effective targeted therapy and prognostic biomarkers. Here, we developed a user-friendly Online Survival analysis web server for GlioBlastoMa, abbreviated OSgbm, to assess the prognostic value of candidate genes. Currently, OSgbm contains 684 samples with transcriptome profiles and clinical information from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Chinese Glioma Genome Atlas (CGGA). The survival analysis results can be graphically presented by Kaplan-Meier (KM) plot with Hazard ratio (HR) and log-rank <italic>p</italic> value. As demonstration, the prognostic value of 51 previously reported survival associated biomarkers, such as <italic>PROM1</italic> (HR = 2.4120, <italic>p</italic> = 0.0071) and <italic>CXCR4</italic> (HR = 1.5578, <italic>p &lt; </italic>0.001), were confirmed in OSgbm. In summary, OSgbm allows users to evaluate and develop prognostic biomarkers of GBM. The web server of OSgbm is available at <uri xlink:type="simple" xlink:href="http://bioinfo.henu.edu.cn/GBM/GBMList.jsp">http://bioinfo.henu.edu.cn/GBM/GBMList.jsp</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>glioblastoma</kwd>
      <kwd>survival analysis</kwd>
      <kwd>prognostic biomarker</kwd>
      <kwd>OSgbm</kwd>
      <kwd>transcriptome profiles</kwd>
      <kwd>clinical information</kwd>
    </kwd-group>
    <counts>
      <fig-count count="1"/>
      <table-count count="2"/>
      <equation-count count="0"/>
      <ref-count count="67"/>
      <page-count count="8"/>
      <word-count count="3558"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS) and causes a high mortality rate (<xref rid="B40" ref-type="bibr">Nikiforova and Hamilton, 2011</xref>; <xref rid="B50" ref-type="bibr">Stoyanov et al., 2018</xref>). Although many new therapies have improved the clinical outcome and more clinical trials have demonstrated the high efficacy in treating GBM, the survival rate of GBM patients is still low. GBM is a complex disease to tackle with a median survival period of approximately 14 months, and a 5-year survival rate of 5% (<xref rid="B51" ref-type="bibr">Stupp et al., 2005</xref>; <xref rid="B26" ref-type="bibr">Johnson and O'Neill, 2012</xref>; <xref rid="B42" ref-type="bibr">Polivka et al., 2017</xref>). Prognostic biomarkers have been showing great roles in cancer patient management and may guide targeted therapies. Therefore, it is greatly needed to investigate prognostic biomarkers in GBM.</p>
    <p>Previous studies have reported some prognostic biomarkers in GBM, such as gene mutation of gene <italic>IDH</italic> and <italic>PTEN</italic>, and expression variation of gene <italic>CD133</italic> (<xref rid="B61" ref-type="bibr">Yang et al., 2016</xref>; <xref rid="B5" ref-type="bibr">Cai and Sughrue, 2017</xref>; <xref rid="B39" ref-type="bibr">Nguyen et al., 2018</xref>). However, these biomarkers have not been translated to clinical applications due to the lack of independent validation. In addition, due to the molecular heterogeneity among GBMs and limited patient samples (<xref rid="B37" ref-type="bibr">Nathanson et al., 2014</xref>; <xref rid="B2" ref-type="bibr">Aldape et al., 2015</xref>; <xref rid="B4" ref-type="bibr">Brown et al., 2017</xref>), the prognostic behavior of a certain biomarker may be inconsistent or even contradictory between different reports. In other words, cross population validation in a larger patient cohort is critical for evaluating the prognostic biomarker.</p>
    <p>In current work, we collected the gene expression profiles and clinical information of 684 GBM patients from seven independent cohorts obtained from TCGA, GEO and CGGA. We developed a user-friendly web server, OSgbm, to analyze the prognostic value of genes of interests. With this web server, it would facilitate researchers and clinicians to screen, develop and validate new prognostic biomarkers in GBM.</p>
  </sec>
  <sec id="s2">
    <title>Methods</title>
    <sec id="s2_1">
      <title>Datasets Collection</title>
      <p>GBM datasets are from three major data sources. First, level-3 gene expression profiling data (HiSeqV2) and clinical information of GBM samples were downloaded from TCGA on April 2018 (<uri xlink:type="simple" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</uri>). Second, four cohorts (≥30 cases) with available gene expression profiles and clinical survival information were collected from GEO database (<uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</uri>). Third, two GBM cohorts were gathered from CGGA (<uri xlink:type="simple" xlink:href="http://www.cgga.org.cn/">http://www.cgga.org.cn/</uri>). After an initial filtration and quality check (with available gene expression profiling data and clinical survival information), 153 samples from TCGA, 276 samples from GEO, and 255 samples from CGGA were included for the following database and web server construction. The histology of recurrent GBM (rGBM) were included in GSE7696 (10 samples), GSE42669 (11 samples), CGGAarray (9 samples) and CGGAseq (22 samples) datasets. Two CGGA datasets also included 20 samples of secondary GBM (sGBM).</p>
    </sec>
    <sec id="s2_2">
      <title>System Implementation and Server Set-Up</title>
      <p>OSgbm is a web-based tool which uses J2EE (Java 2 Platform Enterprise Edition) architecture as we previously described (<xref rid="B54" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="B55" ref-type="bibr">Wang et al., 2019</xref>; <xref rid="B58" ref-type="bibr">Xie et al., 2019a</xref>; <xref rid="B65" ref-type="bibr">Zhang et al., 2019</xref>). The gene expression and clinical data were integrated in the background database, which was handled by a MySQL server. Dynamic web interfaces were written in HTML 5.0 and hosted by Tomcat on Windows Server. Using OSgbm requires a HTML 5.0-compliant browser with JavaScript enabled, but does not require any particular visual plug-in tool. Since the web server was designed for users with no specialized bioinformatics skills, we propose ‘out-of-the-box’ data. The input of OSgbm web server is official gene symbol. For the “Data Source: Combined” option, as all the datasets used in OSgbm already have been published, processed and normalized well, in order to avoid of the batch effect and platform biases among these datasets, we first stratify the patients into high- and low-expression group for the input gene in each dataset, and then merged relative patients from high- and low-expression group from each dataset into a combined high-expression group (Upper group in the Kaplan–Meier plot) and a combined low-expression group (Lower group in the Kaplan–Meier plot) for the analysis of Kaplan–Meier plot and log-rank test. The statistical analyses of input were performed with R package: KM curves with Hazard ratio (HR, 95% confidence interval) and log-rank <italic>p</italic> value were calculated by R package ‘survival’. OSgbm is available at <uri xlink:type="simple" xlink:href="http://bioinfo.henu.edu.cn/GBM/GBMList.jsp">http://bioinfo.henu.edu.cn/GBM/GBMList.jsp</uri>.</p>
    </sec>
    <sec id="s2_3">
      <title>Validation of Previously Reported Prognostic Biomarkers</title>
      <p>A PubMed search was performed to identify previously reported GBM prognostic biomarkers, using keywords ‘glioblastoma’, ‘survival’ and ‘biomarker’. Totally, 53 prognostic biomarkers were identified from 2013 publications. The flow chart of biomarker collection was showed in <xref ref-type="supplementary-material" rid="SM1"><bold>Figure S1</bold></xref>. The prognostic values of these published biomarkers were analyzed in either a form of combined cohorts of all GBM patients or in a single cohort in our database.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>The Clinical Characteristics of GBM Datasets Used in OSgbm</title>
      <p>In OSgbm, we included a total of 684 unique GBM samples from seven datasets, including one TCGA cohort, four GEO cohorts and two CGGA cohorts. The survival information includes overall survival (OS), disease specific survival (DSS), disease free interval (DFI) and progression free interval (PFI) (<xref rid="B29" ref-type="bibr">Liu et al., 2018</xref>). The confounding clinical factors, such as age, grade, gender, histology and treatment regimens were included as well. Clinical characteristics of these datasets in the OSgbm were presented in <xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>. All of the 684 patients have OS data, and the median OS time was 13.44 months, while 153 GBM patients from TCGA cohort have four above mentioned survival terms (OS, DSS, DFI and PFI). The median age of all the patients is 50 years. The death rate is 78.49%. A large proportion of the patients are in grade IV, especially in the two CGGA datasets (99.28% and 100%, respectively).</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Clinical characteristics of each GBM dataset used in OSgbm.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="1" colspan="1">Data<break/>Source</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Sample<break/>Size (n)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Median Age (years)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Death<break/>(%)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">OS Median<break/>(years)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Gender<break/>(male, %)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Grade<break/>(I/II/III/IV, %)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Survival<break/>Terms</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">153</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60</td>
              <td valign="top" align="center" rowspan="1" colspan="1">79.08</td>
              <td valign="top" align="center" rowspan="1" colspan="1">11.90</td>
              <td valign="top" align="center" rowspan="1" colspan="1">64.71</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS, DSS, DFI, PFI</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE7696</td>
              <td valign="top" align="center" rowspan="1" colspan="1">80</td>
              <td valign="top" align="center" rowspan="1" colspan="1">52</td>
              <td valign="top" align="center" rowspan="1" colspan="1">81.25</td>
              <td valign="top" align="center" rowspan="1" colspan="1">15.58</td>
              <td valign="top" align="center" rowspan="1" colspan="1">73.75</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE4412</td>
              <td valign="top" align="center" rowspan="1" colspan="1">85</td>
              <td valign="top" align="center" rowspan="1" colspan="1">42</td>
              <td valign="top" align="center" rowspan="1" colspan="1">69.41</td>
              <td valign="top" align="center" rowspan="1" colspan="1">12.97</td>
              <td valign="top" align="center" rowspan="1" colspan="1">37.65</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0/0/30.59/69.41</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE42669</td>
              <td valign="top" align="center" rowspan="1" colspan="1">57</td>
              <td valign="top" align="center" rowspan="1" colspan="1">51</td>
              <td valign="top" align="center" rowspan="1" colspan="1">80.70</td>
              <td valign="top" align="center" rowspan="1" colspan="1">14.93</td>
              <td valign="top" align="center" rowspan="1" colspan="1">52.63</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE30472</td>
              <td valign="top" align="center" rowspan="1" colspan="1">54</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">88.89</td>
              <td valign="top" align="center" rowspan="1" colspan="1">15.72</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.7/12.96/29.63/53.71</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">128</td>
              <td valign="top" align="center" rowspan="1" colspan="1">48</td>
              <td valign="top" align="center" rowspan="1" colspan="1">66.67</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9.55</td>
              <td valign="top" align="center" rowspan="1" colspan="1">65.22</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0/0/0.72/99.28</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAarray</td>
              <td valign="top" align="center" rowspan="1" colspan="1">127</td>
              <td valign="top" align="center" rowspan="1" colspan="1">47</td>
              <td valign="top" align="center" rowspan="1" colspan="1">83.46</td>
              <td valign="top" align="center" rowspan="1" colspan="1">13.43</td>
              <td valign="top" align="center" rowspan="1" colspan="1">62.20</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0/0/0/100</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Total</td>
              <td valign="top" align="center" rowspan="1" colspan="1">684</td>
              <td valign="top" align="center" rowspan="1" colspan="1">50</td>
              <td valign="top" align="center" rowspan="1" colspan="1">78.49</td>
              <td valign="top" align="center" rowspan="1" colspan="1">13.44</td>
              <td valign="top" align="center" rowspan="1" colspan="1">59.36</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s3_2">
      <title>Set-Up of OSgbm Web Server</title>
      <p>The main function of OSgbm web server is to evaluate and determine the prognostic value of the quested genes. The users start by typing the gene symbol and choosing one dataset of interest or the combined dataset with pooling all the datasets together. To measure the association between a quested gene and survival, GBM samples are categorized according to the median (or other appropriate cutoff value, such as Trichotomy, Quartile) of the selected gene, and KM analysis is used to compare the outcomes between groups (<xref rid="B59" ref-type="bibr">Xie et al., 2019b</xref>). The user could limit the analysis in a subgroup of the patients by setting the age range, grade, gender and so on. Once the gene symbol is input and clinical characters are chosen, OS, DSS, DFI or PFI of each stratified group can be measured and analysis results will be available on the output web page. The prognostic value of each given gene is determined by HR (95% CI) and log-rank <italic>p</italic> value.</p>
    </sec>
    <sec id="s3_3">
      <title>Validation of Previously Reported GBM Prognostic Biomarkers</title>
      <p>To determine the performance of this online tool, 53 previously published GBM prognostic factors collected as the procedure shown in <xref ref-type="supplementary-material" rid="SM1"><bold>Figure S1</bold></xref> and then they were evaluated in OSgbm (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>, <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>) (<xref rid="B47" ref-type="bibr">Sano et al., 1999</xref>; <xref rid="B25" ref-type="bibr">Hung and Howng, 2003</xref>; <xref rid="B23" ref-type="bibr">Heimberger et al., 2005</xref>; <xref rid="B1" ref-type="bibr">Aaberg-Jessen et al., 2009</xref>; <xref rid="B48" ref-type="bibr">Shirai et al., 2009</xref>; <xref rid="B43" ref-type="bibr">Pu et al., 2011</xref>; <xref rid="B11" ref-type="bibr">Cui et al., 2013</xref>; <xref rid="B13" ref-type="bibr">De Tayrac et al., 2013</xref>; <xref rid="B27" ref-type="bibr">Lee et al., 2013</xref>; <xref rid="B45" ref-type="bibr">Rosati et al., 2013</xref>; <xref rid="B53" ref-type="bibr">Wang et al., 2013</xref>; <xref rid="B56" ref-type="bibr">Wu et al., 2013</xref>; <xref rid="B3" ref-type="bibr">Bai et al., 2014</xref>; <xref rid="B19" ref-type="bibr">Han et al., 2014</xref>; <xref rid="B34" ref-type="bibr">Meng et al., 2014</xref>; <xref rid="B41" ref-type="bibr">Olmez et al., 2014</xref>; <xref rid="B67" ref-type="bibr">Zupancic et al., 2014</xref>; <xref rid="B33" ref-type="bibr">Maris et al., 2015</xref>; <xref rid="B35" ref-type="bibr">Moutal et al., 2015</xref>; <xref rid="B60" ref-type="bibr">Yan et al., 2015</xref>; <xref rid="B66" ref-type="bibr">Zhao et al., 2015</xref>; <xref rid="B8" ref-type="bibr">Chaurasia et al., 2016</xref>; <xref rid="B38" ref-type="bibr">Nduom et al., 2016</xref>; <xref rid="B49" ref-type="bibr">Steponaitis et al., 2016</xref>; <xref rid="B49" ref-type="bibr">Steponaitis et al., 2016</xref>; <xref rid="B62" ref-type="bibr">Zhang et al., 2016a</xref>; <xref rid="B63" ref-type="bibr">Zhang et al., 2016b</xref>; <xref rid="B14" ref-type="bibr">Deng et al., 2017</xref>; <xref rid="B15" ref-type="bibr">Dong et al., 2017</xref>; <xref rid="B16" ref-type="bibr">Ge et al., 2017</xref>; <xref rid="B20" ref-type="bibr">Han et al., 2017</xref>; <xref rid="B22" ref-type="bibr">Haynes et al., 2017</xref>; <xref rid="B24" ref-type="bibr">Huang et al., 2017</xref>; <xref rid="B28" ref-type="bibr">Li et al., 2017</xref>; <xref rid="B30" ref-type="bibr">Luo and Zhuang, 2017</xref>; <xref rid="B32" ref-type="bibr">Ma et al., 2017</xref>; <xref rid="B36" ref-type="bibr">Mu et al., 2017</xref>; <xref rid="B46" ref-type="bibr">Roy et al., 2017</xref>; <xref rid="B57" ref-type="bibr">Wu et al., 2017</xref>; <xref rid="B64" ref-type="bibr">Zhang et al., 2017</xref>; <xref rid="B6" ref-type="bibr">Cai et al., 2018</xref>; <xref rid="B7" ref-type="bibr">Cetin et al., 2018</xref>; <xref rid="B9" ref-type="bibr">Cheng et al., 2018</xref>; <xref rid="B10" ref-type="bibr">Chou et al., 2018</xref>; <xref rid="B12" ref-type="bibr">Dahlrot et al., 2018</xref>; <xref rid="B17" ref-type="bibr">Gonçalves et al., 2018</xref>; <xref rid="B21" ref-type="bibr">Hayashi et al., 2018</xref>; <xref rid="B31" ref-type="bibr">Lv et al., 2018</xref>; <xref rid="B44" ref-type="bibr">Qian et al., 2018</xref>; <xref rid="B52" ref-type="bibr">Vasaikar et al., 2018</xref>; <xref rid="B18" ref-type="bibr">Hallal et al., 2019</xref>). OS was selected as the survival term. Among these prognostic genes, 51 of them showed significant prognostic ability in a large-scale combined cohort (33 genes) or in single cohort (18 genes), which were consistent with the prognostic value reported in the literature. The remaining two genes (<italic>IGF1R</italic> and <italic>PCBP2</italic>) display significant prognostic values in OSgbm, but is contradictory to what was reported in the literatures. Both of them were shown as favorable prognostic biomarkers in OSgbm but were reported to be unfavorable GBM prognostic biomarkers in previous reports (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>) (<xref rid="B33" ref-type="bibr">Maris et al., 2015</xref>; <xref rid="B30" ref-type="bibr">Luo and Zhuang, 2017</xref>).</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Validation of previously reported prognostic biomarkers in OSgbm.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="1" colspan="1">Gene symbol</th>
              <th valign="top" align="center" colspan="4" rowspan="1">Validation results</th>
              <th valign="top" align="center" colspan="5" rowspan="1">Literature data</th>
            </tr>
            <tr>
              <th valign="top" rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">OS, HR (95% CI)</th>
              <th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic> Value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Cut Off</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Osgbm</th>
              <th valign="top" align="center" rowspan="1" colspan="1">OS, HR (95% CI)</th>
              <th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic> Value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Sample (n)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Level</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PROM1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.412 (1.040–4.174)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.007</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE7679</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.39 (1.77–3.23)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">656</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B62" ref-type="bibr">Zhang et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>SRGN</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.371 (1.256–4.477)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.008</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.037</td>
              <td valign="top" align="center" rowspan="1" colspan="1">504</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B46" ref-type="bibr">Roy et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>EDNRB</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.272 (1.115–4.627)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.024</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE30472</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.86 (1.12–7.34)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.031</td>
              <td valign="top" align="center" rowspan="1" colspan="1">25</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">Vasaikar et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PSMB4</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.074 (1.187–3.626)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.010</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">77</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B9" ref-type="bibr">Cheng et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>WNT6</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.035 (1.098–3.770)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.024</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="center" rowspan="1" colspan="1">16</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B17" ref-type="bibr">Gonçalves et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>DPYSL5</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.023 (1.160–3.527)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.013</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAarray</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.026</td>
              <td valign="top" align="center" rowspan="1" colspan="1">183</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B35" ref-type="bibr">Moutal et al., 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IL17A</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.009 (1.107–3.646)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.022</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50% vs Lower 50%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE30472</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.007</td>
              <td valign="top" align="center" rowspan="1" colspan="1">41</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B11" ref-type="bibr">Cui et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TLR9</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.976 (1.089–3.588)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.025</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAseq</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.020</td>
              <td valign="top" align="center" rowspan="1" colspan="1">46</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B36" ref-type="bibr">Mu et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>ACKR3</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.974 (1.040–3.747)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.038</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE7679</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.56 (1.04–2.51)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">146</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B14" ref-type="bibr">Deng et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>H19</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.864 (1.309–2.653)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.034</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">Wu et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>EGFR</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.845 (1.077–3.160)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.026</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE7696</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">196</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">Heimberger et al., 2005</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>NUSAP1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.748 (1.006–3.040</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.048</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAarray</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.65 (0.49–0.86)*</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.003</td>
              <td valign="top" align="center" rowspan="1" colspan="1">518</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B44" ref-type="bibr">Qian et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CHAF1B</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.707 (1.323–2.203)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="center" rowspan="1" colspan="1">96</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">De Tayrac et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TAGLN2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.665 (1.282–2.161)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">667</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">Han et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>BIRC1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.658 (1.266–2.172)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0003</td>
              <td valign="top" align="center" rowspan="1" colspan="1">66</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">Shirai et al., 2009</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>MGMT</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.633 (1.260–2.115)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.50</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.01</td>
              <td valign="top" align="center" rowspan="1" colspan="1">157</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B12" ref-type="bibr">Dahlrot et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CD70</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.561 (1.180–2.065)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.002</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6 (0.98–2.51)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.046</td>
              <td valign="top" align="center" rowspan="1" colspan="1">107</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B16" ref-type="bibr">Ge et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CXCR4</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.558 (1.207–2.010)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">156</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B32" ref-type="bibr">Ma et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CA9</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.556 (1.202–2.015)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="center" rowspan="1" colspan="1">66</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B7" ref-type="bibr">Cetin et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PDCD1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.508 (1.171–1.942)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.002</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.028</td>
              <td valign="top" align="center" rowspan="1" colspan="1">149</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B38" ref-type="bibr">Nduom et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IDH1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.490 (1.013–2.192)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.043</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50% vs Lower 50%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAarray</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.045</td>
              <td valign="top" align="center" rowspan="1" colspan="1">163</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B8" ref-type="bibr">Chaurasia et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IGFBP2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.467 (1.132–1.902)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.04 (1.02–1.05)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">83</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Plasma</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">Han et al., 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PBK</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.456 (1.131–1.875)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.007</td>
              <td valign="top" align="center" rowspan="1" colspan="1">32</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">Hayashi et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>EFEMP2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.446 (1.117–1.871)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.005</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.01</td>
              <td valign="top" align="center" rowspan="1" colspan="1">77</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">Li et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>MET</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.434 (1.130–1.820)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.003</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1–2.2)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">69</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">Olmez et al., 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CHI3L1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.438 (1.104–1.872)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.007</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE30472</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.01</td>
              <td valign="top" align="center" rowspan="1" colspan="1">98</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B49" ref-type="bibr">Steponaitis et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TRAF2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.443 (1.118–1.863)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.005</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">105</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B64" ref-type="bibr">Zhang et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>HMGB2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.391 (1.099–1.759)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.006</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.35 (1.25–9.02)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.017</td>
              <td valign="top" align="center" rowspan="1" colspan="1">51</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">Wu et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>MCM6</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.387 (1.132–1.699)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.002</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.19</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.006</td>
              <td valign="top" align="center" rowspan="1" colspan="1">325</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B6" ref-type="bibr">Cai et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CD44</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.386 (1.073–1.790)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.012</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">28</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B49" ref-type="bibr">Steponaitis et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TIMP1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.342 (1.025–1.758)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.033</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.2 (1.5–6.7)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="center" rowspan="1" colspan="1">112</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B1" ref-type="bibr">Aaberg-Jessen et al., 2009</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CD151</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.336 (1.023–1.746)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.034</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5.064 (1.427–17.969)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.012</td>
              <td valign="top" align="center" rowspan="1" colspan="1">211</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">Lee et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TWIST1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.312 (1.013–1.699)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.039</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5.745 (1.331–1.89)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.017</td>
              <td valign="top" align="center" rowspan="1" colspan="1">86</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">Wang et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CCT6A</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.316 (1.045–1.655)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.019</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.21 (2.85–3.65)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.006</td>
              <td valign="top" align="center" rowspan="1" colspan="1">497</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B18" ref-type="bibr">Hallal et al., 2019</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>APC</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.308 (1.093–1.566)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50% vs Lower 50%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">83</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">Rosati et al., 2013</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CD247</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.292 (1.022–1.633)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.032</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.54 (1.05–2.28)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.023</td>
              <td valign="top" align="center" rowspan="1" colspan="1">149</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B38" ref-type="bibr">Nduom et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>CXCR3</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.272 (1.027–1.575)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.028</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.56 (1.04–2.51)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.03</td>
              <td valign="top" align="center" rowspan="1" colspan="1">146</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">Pu et al., 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TCTN1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.223 (1.011–1.493)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.039</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 70%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.32 (1.08–1.61)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.006</td>
              <td valign="top" align="center" rowspan="1" colspan="1">518</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B34" ref-type="bibr">Meng et al., 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>BICD1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.794 (0.644–0.978)<sup>#</sup>
</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.030</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Lower 25% vs Upper 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.577 (1.299–1.914)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">523</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">Huang et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IFIT1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.770 (0.609–0.973)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.029</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.22 (0.10–0.52)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">70</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B63" ref-type="bibr">Zhang et al., 2016</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>BRMS1L</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.753 (0.587–0.966)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.026</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">60</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">Lv et al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>IGF1R</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.745 (0.588–0.944)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.015</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.65 (1.10–2.47)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.016</td>
              <td valign="top" align="center" rowspan="1" colspan="1">167</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B33" ref-type="bibr">Maris et al., 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>GANO1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.748 (0.585–0.957)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.021</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.009</td>
              <td valign="top" align="center" rowspan="1" colspan="1">178</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B67" ref-type="bibr">Zupancic et al., 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PTEN</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.729 (0.567–0.938)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.014</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.3 (1.6–4.3)*</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0003</td>
              <td valign="top" align="center" rowspan="1" colspan="1">61</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">Sano et al., 1999</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>SEMA6A</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.694 (0.556–0.867)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.71 (1.01–2.65)*</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.012</td>
              <td valign="top" align="center" rowspan="1" colspan="1">200</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B66" ref-type="bibr">Zhao et al., 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PHF3</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.683 (0.529–0.883)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.004</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.44 (0.26–0.77)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0031</td>
              <td valign="top" align="center" rowspan="1" colspan="1">35</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">Yan et al., 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PPARα</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.644 (0.503–0.825)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.31 (1.05–1.63)*</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.016</td>
              <td valign="top" align="center" rowspan="1" colspan="1">473</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">Haynes et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PCBP2</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.632 (0.417–0.957)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.031</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 75%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">130</td>
              <td valign="top" align="left" rowspan="1" colspan="1">mRNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">Luo and Zhuang, 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>LAPTM4B</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.626 (0.433–0.894)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.010</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50% vs Lower 50%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">39</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B15" ref-type="bibr">Dong et al., 2017</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>ANXA7</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.619 (0.475–0.806)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Combined</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">99</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">Hung and Howng, 2003</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>PHF20</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.557 (0.319–0.972)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.040</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50% vs Lower 50%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">CGGAarray</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.5 (0.29–0.86)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.012</td>
              <td valign="top" align="center" rowspan="1" colspan="1">62</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B60" ref-type="bibr">Yan et al., 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>TES</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.407 (0.173–0.958)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.040</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30% vs Lower 30%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE42669</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" align="center" rowspan="1" colspan="1">37</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B3" ref-type="bibr">Bai et al., 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
                <italic>LGALS1</italic>
              </td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.368 (0.157–0.863)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.022</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25% vs Lower 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE42669</td>
              <td valign="top" align="center" rowspan="1" colspan="1">–</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.009</td>
              <td valign="top" align="center" rowspan="1" colspan="1">45</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B10" ref-type="bibr">Chou et al., 2018</xref>)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>*: The lower gene expression compared with higher gene expression in the literature data.</p>
          <p><sup>#</sup>: The lower gene expression compared with higher gene expression in the OSgbm data.</p>
        </table-wrap-foot>
      </table-wrap>
      <fig id="f1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Analysis of the prognostic value of <italic>MGMT</italic> in OSgbm. <bold>(A)</bold> The options of input parameters used in the prognostic analysis of <italic>MGMT</italic> in OSgbm. <bold>(B)</bold> The output web page of prognosis analysis of <italic>MGMT</italic> using a combined cohort with pooling all datasets together in OSgbm. <bold>(C)</bold> The OSgbm output of gene <italic>MGMT</italic> in single cohort.</p>
        </caption>
        <graphic xlink:href="fgene-10-01378-g001"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>The development of prognostic biomarkers is important for guiding the treatments especially for therapy-resistant GBM patients. In our work, we developed a new web server, OSgbm, to help researchers to evaluate the prognostic value of a given gene for GBM patients. OSgbm is easy to use and requires no special skills (such as bioinformatics training). With filtering by one or several clinical confounding factors provided in OSgbm, users can also evaluate the prognostic value of their interested genes according to their special needs. The function and performance tests of OSgbm web server showed that 96% (51 out of 53) of previously reported prognostic biomarkers could be confirmed in OSgbm, which indicates that these biomarkers validated in independent cohorts have the potency of translating to clinical applications, and also indicates the well performance of OSgbm. Nevertheless, there are two genes including <italic>IGF1R</italic> and <italic>PCBP2</italic> which showed different prognostic values to the literatures, the discrepancy of prognostic performance of <italic>IGF1R</italic> and <italic>PCBP2</italic> between OSgbm and literatures may be caused by race, different cohort size, or analysis level and methods (mRNA vs. protein, gene microarray vs. immunohistochemistry) (<xref rid="B33" ref-type="bibr">Maris et al., 2015</xref>; <xref rid="B30" ref-type="bibr">Luo and Zhuang, 2017</xref>). For example, the race reported in literatures for <italic>PCBP2</italic> is Asian, while that in validated cohort of OSgbm is mostly White. The mRNA level was analyzed in OSgbm for <italic>IGF1R</italic>, while IGF1R was determined by immunohistochemistry in literature. In addition, the race analyzed in OSgbm for <italic>IGF1R</italic> is Asian (Korea for GSE42669 and Chinese for CGGA), while the race reported in literature for IGF1R is European. As a result, it will be necessary to validate the prognostic performance of <italic>IGF1R</italic> and <italic>PCBP2</italic> in a larger independent cohort of glioblastoma.</p>
    <p>In conclusion, OSgbm is a user-friendly web server to help researchers and clinicians to identify suitable prognostic biomarkers in GBM. Furthermore, we will keep update the database of OSgbm to collect more and more GBM datasets when new GBM dataset is available, and will implement the multivariate cox proportional hazards model into OSgbm for the purpose of adjustment for the confounding clinical factors, and we also encourage users to contact us to upload their own data into OSgbm.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>All datasets for this study are included in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>.</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>XG conceived and directed the project. HD and QW collected data and developed the web server. HD, NL, JL, LG, MY, GZ, YA, FW, LX, and YL performed data analysis. WZ, HZ, and MZ contributed to data analysis and paper writing. XG and HD wrote the manuscript with the assistance and approval of all authors.</p>
  </sec>
  <sec id="s7">
    <title>Conflict of Interest</title>
    <p>Author MZ is employed by company of Nanjing Jiliang Biotechnology Co., Ltd.</p>
    <p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgments</title>
    <p>This work was supported by the National Natural Science Foundation of China (No. 81602362), the program for Science and Technology Development in Henan Province (No. 162102310391), the supporting grants of Henan University (No. 2015YBZR048; No. B2015151), the program for Innovative Talents of Science and Technology in Henan Province (No. 18HASTIT048), and Yellow River Scholar Program (No. H2016012), Kaifeng Science and Technology Major Project (No. 18ZD008).</p>
  </ack>
  <sec sec-type="supplementary-material" id="s8">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fgene.2019.01378/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2019.01378/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SM1">
      <media xlink:href="Image_1.jpeg">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaberg-Jessen</surname><given-names>C.</given-names></name><name><surname>Christensen</surname><given-names>K.</given-names></name><name><surname>Offenberg</surname><given-names>H.</given-names></name><name><surname>Bartels</surname><given-names>A.</given-names></name><name><surname>Dreehsen</surname><given-names>T.</given-names></name><name><surname>Hansen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival</article-title>. <source>J. Neurooncol.</source>
<volume>95</volume>, <fpage>117</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-009-9910-8</pub-id>
<pub-id pub-id-type="pmid">19430729</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aldape</surname><given-names>K.</given-names></name><name><surname>Zadeh</surname><given-names>G.</given-names></name><name><surname>Mansouri</surname><given-names>S.</given-names></name><name><surname>Reifenberger</surname><given-names>G.</given-names></name><name><surname>von Deimling</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Glioblastoma: pathology, molecular mechanisms and markers</article-title>. <source>Acta Neuropathol.</source>
<volume>129</volume>, <fpage>829</fpage>–<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-015-1432-1</pub-id>
<pub-id pub-id-type="pmid">25943888</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2014</year>). <article-title>Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome</article-title>. <source>Eur. J. Med. Res.</source>
<volume>19</volume>, <fpage>66</fpage>. <pub-id pub-id-type="doi">10.1186/s40001-014-0066-4</pub-id>
<pub-id pub-id-type="pmid">25498217</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>D. V.</given-names></name><name><surname>Filiz</surname><given-names>G.</given-names></name><name><surname>Daniel</surname><given-names>P. M.</given-names></name><name><surname>Hollande</surname><given-names>F.</given-names></name><name><surname>Dworkin</surname><given-names>S.</given-names></name><name><surname>Amiridis</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity</article-title>. <source>PloS One</source>
<volume>12</volume>, <fpage>e0172791</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0172791</pub-id>
<pub-id pub-id-type="pmid">28241049</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Sughrue</surname><given-names>M. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Glioblastoma: new therapeutic strategies to address cellular and genomic complexity</article-title>. <source>Oncotarget</source>
<volume>20</volume>, <fpage>9540</fpage>–<lpage>9554</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.23476</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hao</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Overexpression of MCM6 predicts poor survival in patients with glioma</article-title>. <source>Hum. Pathol.</source>
<volume>78</volume>, <fpage>182</fpage>–<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2018.04.024</pub-id>
<pub-id pub-id-type="pmid">29753008</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cetin</surname><given-names>B.</given-names></name><name><surname>Gonul</surname><given-names>I. I.</given-names></name><name><surname>Gumusay</surname><given-names>O.</given-names></name><name><surname>Bilgetekin</surname><given-names>I.</given-names></name><name><surname>Algin</surname><given-names>E.</given-names></name><name><surname>Ozet</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme</article-title>. <source>Neuropathology</source>
<volume>38</volume>, <fpage>457</fpage>–<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1111/neup.12485.</pub-id>
<pub-id pub-id-type="pmid">29952031</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaurasia</surname><given-names>A.</given-names></name><name><surname>Park</surname><given-names>S. H.</given-names></name><name><surname>Seo</surname><given-names>J. W.</given-names></name><name><surname>Park</surname><given-names>C. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival</article-title>. <source>J. Korean Med. Sci.</source>
<volume>31</volume>, <fpage>1208</fpage>–<lpage>1214</lpage>. <pub-id pub-id-type="doi">10.3346/jkms.2016.31.8.1208</pub-id>
<pub-id pub-id-type="pmid">27478330</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Tsai</surname><given-names>W.</given-names></name><name><surname>Sung</surname><given-names>Y.</given-names></name><name><surname>Chang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Interference with PSMB4 expression exerts an anti-tumor effect by decreasing the invasion and proliferation of human glioblastoma cells</article-title>. <source>Cell Physiol. Biochem.</source>
<volume>45</volume>, <fpage>819</fpage>–<lpage>831</lpage>. <pub-id pub-id-type="doi">10.1159/000487174</pub-id>
<pub-id pub-id-type="pmid">29414809</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>S.</given-names></name><name><surname>Yen</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy</article-title>. <source>BMC Cancer</source>
<volume>18</volume>, <fpage>105</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-018-4025-2</pub-id>
<pub-id pub-id-type="pmid">29378529</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Sui</surname><given-names>D.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>9</volume>, <fpage>134</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.4891</pub-id>
<pub-id pub-id-type="pmid">23411595</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlrot</surname><given-names>R. H.</given-names></name><name><surname>Dowsett</surname><given-names>J.</given-names></name><name><surname>Fosmark</surname><given-names>S.</given-names></name><name><surname>Malmström</surname><given-names>A.</given-names></name><name><surname>Henriksson</surname><given-names>R.</given-names></name><name><surname>Boldt</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis</article-title>. <source>Neuropathol. Appl. Neurobiol.</source>
<volume>44</volume>, <fpage>172</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1111/nan.12415</pub-id>
<pub-id pub-id-type="pmid">28574607</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Tayrac</surname><given-names>M.</given-names></name><name><surname>Saikali</surname><given-names>S.</given-names></name><name><surname>Aubry</surname><given-names>M.</given-names></name><name><surname>Bellaud</surname><given-names>P.</given-names></name><name><surname>Boniface</surname><given-names>R.</given-names></name><name><surname>Quillien</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas</article-title>. <source>PloS One</source>
<volume>8</volume>, <fpage>e73332</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0073332</pub-id>
<pub-id pub-id-type="pmid">24039914</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Chemokine receptor CXCR7 is an independent prognostic biomarker in glioblastoma</article-title>. <source>Cancer Biomark.</source>
<volume>20</volume>, <fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3233/CBM-151430</pub-id>
<pub-id pub-id-type="pmid">28759950</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>D.</given-names></name><name><surname>Ando</surname><given-names>N.</given-names></name><name><surname>Sumita</surname><given-names>K.</given-names></name><name><surname>Maehara</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>LAPTM4B-35 is a novel prognostic factor for glioblastoma</article-title>. <source>J. Neurooncol.</source>
<volume>132</volume>, <fpage>295</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-017-2369-0</pub-id>
<pub-id pub-id-type="pmid">28097442</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Mu</surname><given-names>L.</given-names></name><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Long</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM</article-title>. <source>Int. J. Cancer</source>
<volume>141</volume>, <fpage>1434</fpage>–<lpage>1444</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.30830</pub-id>
<pub-id pub-id-type="pmid">28612394</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>C. S.</given-names></name><name><surname>Vieira de Castro</surname><given-names>J.</given-names></name><name><surname>Pojo</surname><given-names>M.</given-names></name><name><surname>Martins</surname><given-names>E. P.</given-names></name><name><surname>Queirós</surname><given-names>S.</given-names></name><name><surname>Chautard</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma</article-title>. <source>Theranostics</source>
<volume>8</volume>, <fpage>4805</fpage>–<lpage>4823</lpage>. <pub-id pub-id-type="doi">10.7150/thno.25025</pub-id>
<pub-id pub-id-type="pmid">30279739</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallal</surname><given-names>S.</given-names></name><name><surname>Russell</surname><given-names>B. P.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>M. Y. T.</given-names></name><name><surname>Toon</surname><given-names>C. W.</given-names></name><name><surname>Sy</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Extracellular Vesicles from neurosurgical aspirates identifies chaperonin containing TCP1 subunit 6A as a potential glioblastoma biomarker with prognostic significance</article-title>. <source>Proteomics</source>
<volume>19</volume>, <fpage>e1800157</fpage>. <pub-id pub-id-type="doi">10.1002/pmic.201800157</pub-id>
<pub-id pub-id-type="pmid">30451371</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name></person-group> (<year>2014</year>). <article-title>Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients</article-title>. <source>PloS One</source>
<volume>9</volume>, <fpage>e93791</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0093791</pub-id>
<pub-id pub-id-type="pmid">24690948</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ni</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas</article-title>. <source>J. Exp. Clin. Cancer Res.</source>
<volume>36</volume>, <fpage>155</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-017-0619-9</pub-id>
<pub-id pub-id-type="pmid">29110682</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T.</given-names></name><name><surname>Hayakawa</surname><given-names>Y.</given-names></name><name><surname>Koh</surname><given-names>M.</given-names></name><name><surname>Tomita</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>S.</given-names></name><name><surname>Kashiwazaki</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma</article-title>. <source>Neuropathology</source>
<volume>38</volume>, <fpage>144</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1111/neup.12446</pub-id>
<pub-id pub-id-type="pmid">29271010</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname><given-names>H. R.</given-names></name><name><surname>White</surname><given-names>P.</given-names></name><name><surname>Hares</surname><given-names>K. M.</given-names></name><name><surname>Redondo</surname><given-names>J.</given-names></name><name><surname>Kemp</surname><given-names>K. C.</given-names></name><name><surname>Singleton</surname><given-names>W. G. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The transcription factor PPARα is overexpressed and is associated with a favourable prognosis in IDH-wildtype primary glioblastoma</article-title>. <source>Histopathology</source>
<volume>70</volume>, <fpage>1030</fpage>–<lpage>1043</lpage>. <pub-id pub-id-type="doi">10.1111/his.13142</pub-id>
<pub-id pub-id-type="pmid">27926792</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimberger</surname><given-names>A. B.</given-names></name><name><surname>Hlatky</surname><given-names>R.</given-names></name><name><surname>Suki</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Weinberg</surname><given-names>J.</given-names></name><name><surname>Gilbert</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients</article-title>. <source>Clin. Cancer Res.</source>
<volume>11</volume>, <fpage>1462</fpage>–<lpage>1466</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1737</pub-id>
<pub-id pub-id-type="pmid">15746047</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S. P.</given-names></name><name><surname>Chang</surname><given-names>Y. C.</given-names></name><name><surname>Low</surname><given-names>Q. H.</given-names></name><name><surname>Wu</surname><given-names>A. T. H.</given-names></name><name><surname>Chen</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>Y. F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>113766</fpage>–<lpage>113791</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.22667</pub-id>
<pub-id pub-id-type="pmid">29371945</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>K. S.</given-names></name><name><surname>Howng</surname><given-names>S. L.</given-names></name></person-group> (<year>2003</year>). <article-title>Prognostic significance of annexin VII expression in glioblastomas multiforme in humans</article-title>. <source>J. Neurosurg.</source>
<volume>99</volume>, <fpage>886</fpage>–<lpage>892</lpage>. <pub-id pub-id-type="doi">10.3171/jns.2003.99.5.0886</pub-id>
<pub-id pub-id-type="pmid">14609169</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D. R.</given-names></name><name><surname>O'Neill</surname><given-names>B. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Glioblastoma survival in the United States before and during the temozolomide era</article-title>. <source>J. Neurooncol.</source>
<volume>107</volume>, <fpage>359</fpage>–<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.26494</pub-id>
<pub-id pub-id-type="pmid">22045118</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Suh</surname><given-names>Y. L.</given-names></name><name><surname>Park</surname><given-names>T. I.</given-names></name><name><surname>Do</surname><given-names>I. G.</given-names></name><name><surname>Seol</surname><given-names>H. J.</given-names></name><name><surname>Nam</surname><given-names>D. H.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas</article-title>. <source>J. Surg. Oncol.</source>
<volume>107</volume>, <fpage>646</fpage>–<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1002/jso.23249</pub-id>
<pub-id pub-id-type="pmid">22926763</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma</article-title>. <source>Onco. Targets Ther.</source>
<volume>10</volume>, <fpage>387</fpage>–<lpage>395</lpage>. <pub-id pub-id-type="doi">10.2147/OTT.S117165</pub-id>
<pub-id pub-id-type="pmid">28144153</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lichtenberg</surname><given-names>T.</given-names></name><name><surname>Hoadley</surname><given-names>K. A.</given-names></name><name><surname>Poisson</surname><given-names>L. M.</given-names></name><name><surname>Lazar</surname><given-names>A. J.</given-names></name><name><surname>Cherniack</surname><given-names>A. D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>An integrated tcga pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>. <source>Cell</source>
<volume>173</volume>, <fpage>400</fpage>–<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id>
<pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>K.</given-names></name><name><surname>Zhuang</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>High expression of PCBP2 is associated with progression and poor prognosis in patients with glioblastoma</article-title>. <source>BioMed. Pharmacother.</source>
<volume>94</volume>, <fpage>659</fpage>–<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.07.103</pub-id>
<pub-id pub-id-type="pmid">28787701</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>R.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group> (<year>2018</year>). <article-title>Decreased BRMS1L expression is correlated with glioma grade and predicts poor survival in glioblastoma <italic>via an</italic> invasive phenotype</article-title>. <source>Cancer Biomark.</source>
<volume>22</volume>, <fpage>311</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.3233/CBM-171019</pub-id>
<pub-id pub-id-type="pmid">29660900</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Shang</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Lin</surname><given-names>Q.</given-names></name></person-group> (<year>2017</year>). <article-title>CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival</article-title>. <source>Expert Rev. Neurother</source>
<volume>7</volume>, <fpage>941</fpage>–<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1080/14737175.2017.1351299</pub-id>
</mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maris</surname><given-names>C.</given-names></name><name><surname>D'Haene</surname><given-names>N.</given-names></name><name><surname>Trépant</surname><given-names>A. L.</given-names></name><name><surname>Le Mercier</surname><given-names>M.</given-names></name><name><surname>Sauvage</surname><given-names>S.</given-names></name><name><surname>Allard</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>IGF-IR: a new prognostic biomarker for human glioblastoma</article-title>. <source>Br. J. Cancer</source>
<volume>113</volume>, <fpage>729</fpage>–<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2015.242</pub-id>
<pub-id pub-id-type="pmid">26291053</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yun</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Expression and prognostic significance of TCTN1 in human glioblastoma</article-title>. <source>J. Transl. Med.</source>
<volume>12</volume>, <fpage>288</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-014-0288-9</pub-id>
<pub-id pub-id-type="pmid">25304031</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutal</surname><given-names>A.</given-names></name><name><surname>Honnorat</surname><given-names>J.</given-names></name><name><surname>Massoma</surname><given-names>P.</given-names></name><name><surname>Désormeaux</surname><given-names>P.</given-names></name><name><surname>Bertrand</surname><given-names>C.</given-names></name><name><surname>Malleval</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>CRMP5 controls glioblastoma cell proliferation and survival through notch-dependent signaling</article-title>. <source>Cancer Res.</source>
<volume>75</volume>, <fpage>3519</fpage>–<lpage>3528</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0631</pub-id>
<pub-id pub-id-type="pmid">26122847</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Shang</surname><given-names>D.</given-names></name><name><surname>Tan</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Tumor location and survival outcomes in adult patients with supratentorial glioblastoma by levels of toll-like receptor 9 expression</article-title>. <source>World Neurosurg.</source>
<volume>97</volume>, <fpage>279</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1016/j.wneu.2016.10.015</pub-id>
<pub-id pub-id-type="pmid">27744078</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathanson</surname><given-names>D. A.</given-names></name><name><surname>Gini</surname><given-names>B.</given-names></name><name><surname>Mottahedeh</surname><given-names>J.</given-names></name><name><surname>Visnyei</surname><given-names>K.</given-names></name><name><surname>Koga</surname><given-names>T.</given-names></name><name><surname>Gomez</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA</article-title>. <source>Science</source>
<volume>343</volume>, <fpage>72</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1126/science.1241328</pub-id>
<pub-id pub-id-type="pmid">24310612</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nduom</surname><given-names>E. K.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>Yaghi</surname><given-names>N. K.</given-names></name><name><surname>Huang</surname><given-names>N.</given-names></name><name><surname>Kong</surname><given-names>L. Y.</given-names></name><name><surname>Gabrusiewicz</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>PD-L1 expression and prognostic impact in glioblastoma</article-title>. <source>Neuro Oncol.</source>
<volume>18</volume>, <fpage>195</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nov172</pub-id>
<pub-id pub-id-type="pmid">26323609</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>H. S.</given-names></name><name><surname>Shabani</surname><given-names>S.</given-names></name><name><surname>Awad</surname><given-names>A. J.</given-names></name><name><surname>Kaushal</surname><given-names>M.</given-names></name><name><surname>Doan</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Molecular markers of therapy-resistant glioblastoma and potential strategy to combat resistance</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>19</volume>. <pub-id pub-id-type="doi">10.3390/ijms19061765</pub-id>
</mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikiforova</surname><given-names>M. N.</given-names></name><name><surname>Hamilton</surname><given-names>R. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular diagnostics of gliomas</article-title>. <source>Arch. Pathol. Lab. Med.</source>
<volume>135</volume>, <fpage>558</fpage>–<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1043/2010-0649-RAIR.1</pub-id>
<pub-id pub-id-type="pmid">21526954</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmez</surname><given-names>O. F.</given-names></name><name><surname>Cubukcu</surname><given-names>E.</given-names></name><name><surname>Evrensel</surname><given-names>T.</given-names></name><name><surname>Kurt</surname><given-names>M.</given-names></name><name><surname>Avci</surname><given-names>N.</given-names></name><name><surname>Tolunay</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme</article-title>. <source>Clin. Transl. Oncol.</source>
<volume>16</volume>, <fpage>173</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1007/s12094-013-1059-4</pub-id>
<pub-id pub-id-type="pmid">23740136</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polivka</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Polivka</surname><given-names>J.</given-names></name><name><surname>Holubec</surname><given-names>L.</given-names></name><name><surname>Kubikova</surname><given-names>T.</given-names></name><name><surname>Priban</surname><given-names>V.</given-names></name><name><surname>Hes</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme</article-title>. <source>Anticancer Res.</source>
<volume>37</volume>, <fpage>21</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.21873/anticanres.11285</pub-id>
<pub-id pub-id-type="pmid">28011470</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Bao</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype</article-title>. <source>J. Neurooncol.</source>
<volume>122</volume>, <fpage>43</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-014-1692-y</pub-id>
</mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Xi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme</article-title>. <source>J. Neurooncol.</source>
<volume>140</volume>, <fpage>199</fpage>–<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-018-2942-1</pub-id>
<pub-id pub-id-type="pmid">29995176</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosati</surname><given-names>A.</given-names></name><name><surname>Poliani</surname><given-names>P. L.</given-names></name><name><surname>Todeschini</surname><given-names>A.</given-names></name><name><surname>Cominelli</surname><given-names>M.</given-names></name><name><surname>Medicina</surname><given-names>D.</given-names></name><name><surname>Cenzato</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme</article-title>. <source>Neuro Oncol.</source>
<volume>15</volume>, <fpage>618</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nos338.</pub-id>
<pub-id pub-id-type="pmid">23410662</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>A.</given-names></name><name><surname>Attarha</surname><given-names>S.</given-names></name><name><surname>Weishaupt</surname><given-names>H.</given-names></name><name><surname>Edqvist</surname><given-names>P. H.</given-names></name><name><surname>Swartling</surname><given-names>F. J.</given-names></name><name><surname>Bergqvist</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Serglycin as a potential biomarker for glioma: association of serglycin expression, extent of mast cell recruitment and glioblastoma progression</article-title>. <source>Oncotarget</source>
<volume>11</volume>, <fpage>24815</fpage>–<lpage>24827</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.15820</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>T.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Langford</surname><given-names>L. A.</given-names></name><name><surname>Koul</surname><given-names>D.</given-names></name><name><surname>Bondy</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis</article-title>. <source>Cancer Res.</source>
<volume>59</volume>, <fpage>1820</fpage>–<lpage>1824</lpage>.<pub-id pub-id-type="pmid">10213484</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Oka</surname><given-names>K.</given-names></name><name><surname>Noda</surname><given-names>S. E.</given-names></name><name><surname>Katoh</surname><given-names>H.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Nuclear survivin expression predicts poorer prognosis in glioblastoma</article-title>. <source>J. Neurooncol.</source>
<volume>91</volume>, <fpage>353</fpage>–<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-008-9720-4</pub-id>
<pub-id pub-id-type="pmid">18953492</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steponaitis</surname><given-names>G.</given-names></name><name><surname>Skiriutė</surname><given-names>D.</given-names></name><name><surname>Kazlauskas</surname><given-names>A.</given-names></name><name><surname>Golubickaitė</surname><given-names>I.</given-names></name><name><surname>Stakaitis</surname><given-names>R.</given-names></name><name><surname>Tamašauskas</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>High CHI3L1 expression is associated with glioma patient survival</article-title>. <source>Diagn. Pathol.</source>
<volume>11</volume>, <fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/s13000-016-0492-4</pub-id>
<pub-id pub-id-type="pmid">27121858</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoyanov</surname><given-names>G. S.</given-names></name><name><surname>Dzhenkov</surname><given-names>D.</given-names></name><name><surname>Ghenev</surname><given-names>P.</given-names></name><name><surname>Iliev</surname><given-names>B.</given-names></name><name><surname>Enchev</surname><given-names>Y.</given-names></name><name><surname>Tonchev</surname><given-names>A. B.</given-names></name></person-group> (<year>2018</year>). <article-title>Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment</article-title>. <source>Med. Oncol.</source>
<volume>35</volume>, <fpage>27</fpage>. <pub-id pub-id-type="doi">10.1007/s12032-018-1083-x</pub-id>
<pub-id pub-id-type="pmid">29387965</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R.</given-names></name><name><surname>Mason</surname><given-names>W. P.</given-names></name><name><surname>van den Bent</surname><given-names>M. J.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>Fisher</surname><given-names>B.</given-names></name><name><surname>Taphoorn</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title>. <source>N Engl. J. Med.</source>
<volume>352</volume>, <fpage>987</fpage>–<lpage>996</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id>
<pub-id pub-id-type="pmid">15758009</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasaikar</surname><given-names>S.</given-names></name><name><surname>Tsipras</surname><given-names>G.</given-names></name><name><surname>Landázuri</surname><given-names>N.</given-names></name><name><surname>Costa</surname><given-names>H.</given-names></name><name><surname>Wilhelmi</surname><given-names>V.</given-names></name><name><surname>Scicluna</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?</article-title>
<source>BMC Cancer</source>
<volume>18</volume>, <fpage>154</fpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.178012</pub-id>
<pub-id pub-id-type="pmid">29409474</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma</article-title>. <source>J. Neurooncol.</source>
<volume>112</volume>, <fpage>339</fpage>–<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-013-1077-7</pub-id>
<pub-id pub-id-type="pmid">23417321</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>OSlms: A web server to evaluate the prognostic value of genes in Leiomyosarcoma</article-title>. <source>Front. Oncol.</source>
<volume>9</volume>, <elocation-id>190</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00190</pub-id>
<pub-id pub-id-type="pmid">30984618</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Xin</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis</article-title>. <source>Oncol. Lett.</source>
<volume>18</volume>, <fpage>1199</fpage>–<lpage>1206</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10440</pub-id>
<pub-id pub-id-type="pmid">31423180</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Xiong</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Mao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance</article-title>. <source>Neuro Oncol.</source>
<volume>15</volume>, <fpage>1264</fpage>–<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/not078</pub-id>
<pub-id pub-id-type="pmid">23828241</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Hu</surname><given-names>Q.</given-names></name><name><surname>Nie</surname><given-names>E.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhi</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Hypoxia induces H19 expression through direct and indirect Hif-1α activity, promoting oncogenic effects in glioblastoma</article-title>. <source>Sci. Rep.</source>
<volume>7</volume>, <fpage>45029</fpage>. <pub-id pub-id-type="doi">10.1038/srep45029</pub-id>
<pub-id pub-id-type="pmid">28327666</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Ge</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2019</year>a). <article-title>OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma</article-title>. <source>Future Oncol</source>
<volume>15</volume>, <fpage>3103</fpage>–<lpage>3110</lpage>. <pub-id pub-id-type="doi">10.2217/fon-2019-0296</pub-id>
<pub-id pub-id-type="pmid">31368353</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>b). <article-title>High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients</article-title>. <source>Genes (Basel)</source>
<volume>10</volume>. <pub-id pub-id-type="doi">10.3390/genes10010036</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Kong</surname><given-names>L. Y.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Gabrusiewicz</surname><given-names>K.</given-names></name><name><surname>Dibra</surname><given-names>D.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival</article-title>. <source>J. Natl. Cancer Inst.</source>
<volume>107</volume> (<issue>8</issue>). <pub-id pub-id-type="doi">10.1002/ijc.20929</pub-id>
</mixed-citation>
    </ref>
    <ref id="B61">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas</article-title>. <source>Neuro Oncol.</source>
<volume>18</volume>, <fpage>1099</fpage>–<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/now021</pub-id>
<pub-id pub-id-type="pmid">26957363</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lv</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>a). <article-title>High CD133 expression is associated with worse prognosis in patients with glioblastoma</article-title>. <source>Mol. Neurobiol.</source>
<volume>53</volume>, <fpage>2354</fpage>–<lpage>2360</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9187-1</pub-id>
<pub-id pub-id-type="pmid">25983032</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>b). <article-title>High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma</article-title>. <source>Hum. Pathol.</source>
<volume>52</volume>, <fpage>136</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.humpath.2016.01.013</pub-id>
<pub-id pub-id-type="pmid">26980050</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Prognostic significance of TNFR-associated factor 1 and 2 (TRAF1 and TRAF2) in glioblastoma</article-title>
<volume>23</volume>,<fpage>4506</fpage>–<lpage>4512</lpage>. <source>Med. Sci. Monit.</source>
<volume>23</volume>, <fpage>4506</fpage>–<lpage>4512</lpage>. <pub-id pub-id-type="doi">10.12659/msm.903397</pub-id>
<pub-id pub-id-type="pmid">28926524</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>Q.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>OSblca: A web server for investigating prognostic biomarkers of bladder cancer patients</article-title>. <source>Front. Oncol.</source>
<volume>9</volume>, <elocation-id>466</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00466</pub-id>
<pub-id pub-id-type="pmid">31275847</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Che</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liang</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>SEMA6A is a prognostic biomarker in glioblastoma</article-title>. <source>Tumour Biol.</source>
<volume>36</volume>, <fpage>8333</fpage>–<lpage>8340</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-015-3584-y</pub-id>
<pub-id pub-id-type="pmid">26014517</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zupancic</surname><given-names>K.</given-names></name><name><surname>Blejec</surname><given-names>A.</given-names></name><name><surname>Herman</surname><given-names>A.</given-names></name><name><surname>Veber</surname><given-names>M.</given-names></name><name><surname>Verbovsek</surname><given-names>U.</given-names></name><name><surname>Korsic</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach</article-title>. <source>Radiol. Oncol.</source>
<volume>48</volume>, <fpage>257</fpage>–<lpage>266</lpage>. <pub-id pub-id-type="doi">10.2478/raon-2014-0014</pub-id>
<pub-id pub-id-type="pmid">25177240</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
